MARKET

ALXN

ALXN

Alexion Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

112.39
+0.15
+0.13%
Closed 18:27 07/01 EDT
OPEN
112.06
PREV CLOSE
112.24
HIGH
113.08
LOW
110.96
VOLUME
1.43M
TURNOVER
--
52 WEEK HIGH
134.84
52 WEEK LOW
72.67
MARKET CAP
24.82B
P/E (TTM)
10.59
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 24 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALXN stock price target is 137.85 with a high estimate of 170.00 and a low estimate of 111.00.

EPS

ALXN News

More
Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More
Zacks · 21h ago
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The busy calendar of June proved positive for drug approvals, with most scheduled events producing positive outcomes. New molecular entity, or NME, approval for the month totaled two, taking the total NME approvals for the year to 24.
Benzinga · 22h ago
Gilead Prices Coronavirus Drug Remdesivir at $390 Per Vial
Zacks · 1d ago
Alexion's European Approval And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 2d ago
Alexion Pharmaceuticals Announces ULTOMIRIS Receives EC Marketing Authorization for Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Pharmaceuticals, Inc.
Benzinga · 3d ago
Alexion Pharma's Ultomiris OK'd in Europe
Seeking Alpha - Article · 3d ago
ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS)
Business Wire · 3d ago
The Week Ahead In Biotech (June 28- July 4): Pending Clinical Readouts In Focus During A Short Holiday Week
Biotech stocks went on a seesaw ride along with the broader markets in the week ended June 26. Yet there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out, forging alliances and adding personnel t
Benzinga · 3d ago

Industry

Pharmaceuticals
+0.39%
Pharmaceuticals & Medical Research
+0.19%

Hot Stocks

Symbol
Price
%Change

About ALXN

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
More

Webull offers kinds of Alexion Pharmaceuticals, Inc. stock information, including NASDAQ:ALXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALXN stock methods without spending real money on the virtual paper trading platform.